Class B shares carry 20 votes each, versus one for Class A. Split-adjusted trading is expected to begin Nov. 24, with GFAI retaining its Nasdaq symbol.
Gold Coast may get $2 million per permit milestone and $3 million six months after commercial production; Blue Moon plans studies for possible Nevada processing.
Existing policies remain in force, with servicing contacts and processes unchanged; CareScout plans to broaden services with insurers and care providers.
A $7.62 million investment loss and lower gross profit drove the shift from $1.38 million profit; cash and equivalents stood at $13.15 million on June 30.
Priced at 99.486% of par, the unsecured notes are guaranteed by GLPI; proceeds may fund development, acquisitions or debt repayment, with closing expected Dec. 1.
Median progression-free survival was 12.8 months among 61 patients, with 18.3 months' median follow-up; the data support the ongoing Phase 3 RASolute 303 trial.
Net loss widened to $6.4 million as gross margin fell to 11.0% from 15.1%; inventory fell to $6.5 million from $15.9 million, and all bank borrowings were repaid.